PRODIGE 115 (FFCD 2406) ULYSSE : FOLFOX/FOLFIRI + Bévacizumab ou Fruquintinib en 2ème ligne du Cancer Colorectal métastatique (CCRm) : essai de phase II randomisée non comparative ULYSSE (PRODIGE 115 – FFCD 2406)

Not yet translated Not yet translated
Authors
Category Primary study
Registry of TrialsClinical Trials Information System
Year 2025
This article has no abstract
Epistemonikos ID: 7b7964ebc95c6445015a00950eaaa80c632cccb7
First added on: Jan 17, 2026